298 related articles for article (PubMed ID: 30646339)
1. Association of Concomitant Use of Cholinesterase Inhibitors or Memantine With Cognitive Decline in Alzheimer Clinical Trials: A Meta-analysis.
Kennedy RE; Cutter GR; Fowler ME; Schneider LS
JAMA Netw Open; 2018 Nov; 1(7):e184080. PubMed ID: 30646339
[TBL] [Abstract][Full Text] [Related]
2. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease.
Lopez OL; Becker JT; Wahed AS; Saxton J; Sweet RA; Wolk DA; Klunk W; Dekosky ST
J Neurol Neurosurg Psychiatry; 2009 Jun; 80(6):600-7. PubMed ID: 19204022
[TBL] [Abstract][Full Text] [Related]
3. Memantine for dementia.
McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
[TBL] [Abstract][Full Text] [Related]
4. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.
Porsteinsson AP; Grossberg GT; Mintzer J; Olin JT;
Curr Alzheimer Res; 2008 Feb; 5(1):83-9. PubMed ID: 18288936
[TBL] [Abstract][Full Text] [Related]
5. Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative.
Schneider LS; Insel PS; Weiner MW;
Arch Neurol; 2011 Jan; 68(1):58-66. PubMed ID: 21220675
[TBL] [Abstract][Full Text] [Related]
6. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.
Tariot PN; Farlow MR; Grossberg GT; Graham SM; McDonald S; Gergel I;
JAMA; 2004 Jan; 291(3):317-24. PubMed ID: 14734594
[TBL] [Abstract][Full Text] [Related]
7. Memantine and Acetylcholinesterase Inhibitor Use in Alzheimer's Disease Clinical Trials: Potential for Confounding by Indication.
Huisa BN; Thomas RG; Jin S; Oltersdorf T; Taylor C; Feldman HH
J Alzheimers Dis; 2019; 67(2):707-713. PubMed ID: 30636733
[TBL] [Abstract][Full Text] [Related]
8. Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.
Dysken MW; Sano M; Asthana S; Vertrees JE; Pallaki M; Llorente M; Love S; Schellenberg GD; McCarten JR; Malphurs J; Prieto S; Chen P; Loreck DJ; Trapp G; Bakshi RS; Mintzer JE; Heidebrink JL; Vidal-Cardona A; Arroyo LM; Cruz AR; Zachariah S; Kowall NW; Chopra MP; Craft S; Thielke S; Turvey CL; Woodman C; Monnell KA; Gordon K; Tomaska J; Segal Y; Peduzzi PN; Guarino PD
JAMA; 2014 Jan; 311(1):33-44. PubMed ID: 24381967
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing.
Blaszczyk AT; Mang BH; Garza H; Mathys M
Consult Pharm; 2018 May; 33(5):273-282. PubMed ID: 29789049
[TBL] [Abstract][Full Text] [Related]
10. Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis.
Kishi T; Matsunaga S; Oya K; Nomura I; Ikuta T; Iwata N
J Alzheimers Dis; 2017; 60(2):401-425. PubMed ID: 28922160
[TBL] [Abstract][Full Text] [Related]
11. EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease.
Schmidt R; Hofer E; Bouwman FH; Buerger K; Cordonnier C; Fladby T; Galimberti D; Georges J; Heneka MT; Hort J; Laczó J; Molinuevo JL; O'Brien JT; Religa D; Scheltens P; Schott JM; Sorbi S
Eur J Neurol; 2015 Jun; 22(6):889-98. PubMed ID: 25808982
[TBL] [Abstract][Full Text] [Related]
12. Memantine ER Maintains Patient Response in Moderate to Severe Alzheimer's Disease: Post Hoc Analyses From a Randomized, Controlled, Clinical Trial of Patients Treated With Cholinesterase Inhibitors.
Grossberg GT; Alva G; Hendrix S; Ellison N; Kane MC; Edwards J
Alzheimer Dis Assoc Disord; 2018; 32(3):173-178. PubMed ID: 29771687
[TBL] [Abstract][Full Text] [Related]
13. Lack of evidence for the efficacy of memantine in mild Alzheimer disease.
Schneider LS; Dagerman KS; Higgins JP; McShane R
Arch Neurol; 2011 Aug; 68(8):991-8. PubMed ID: 21482915
[TBL] [Abstract][Full Text] [Related]
14. The impact of memantine and cholinesterase inhibitor initiation for Alzheimer disease on the use of antipsychotic agents: analysis using the Régie de l'Assurance Maladie du Québec database.
Lachaine J; Beauchemin C; Crochard A; Bineau S
Can J Psychiatry; 2013 Apr; 58(4):195-200. PubMed ID: 23547642
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Alzheimer's disease in the long-term-care setting.
Smith DA
Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
[TBL] [Abstract][Full Text] [Related]
16. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
Wattmo C; Wallin ÅK
Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
[TBL] [Abstract][Full Text] [Related]
17. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
[TBL] [Abstract][Full Text] [Related]
18. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal medication usage in Alzheimer disease patients.
Zhu CW; Livote EE; Kahle-Wrobleski K; Scarmeas N; Albert M; Brandt J; Blacker D; Sano M; Stern Y
Alzheimer Dis Assoc Disord; 2010; 24(4):354-9. PubMed ID: 20625271
[TBL] [Abstract][Full Text] [Related]
20. Dementia medications and risk of falls, syncope, and related adverse events: meta-analysis of randomized controlled trials.
Kim DH; Brown RT; Ding EL; Kiel DP; Berry SD
J Am Geriatr Soc; 2011 Jun; 59(6):1019-31. PubMed ID: 21649634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
